| Literature DB >> 30618880 |
Wai Tong Chien1, Daniel Bressington2, Sally W C Chan3.
Abstract
Introduction: Recent research in Western countries has indicated that family interventions in schizophrenia and other psychotic disorders can reduce patient relapse and improve medication compliance. Few studies have addressed Chinese and Asian populations. This study tested the long-term effects of a 9-month family-led mutual support group for Chinese people with schizophrenia in Hong Kong, compared with psycho-education and standard psychiatric care.Entities:
Keywords: family intervention; mutual support group; psycho-education; randomized controlled trial; recent-onset psychosis
Year: 2018 PMID: 30618880 PMCID: PMC6305581 DOI: 10.3389/fpsyt.2018.00710
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Figure 1Flow diagram of the controlled trial procedure. The figure shows the main procedure of this randomized controlled trial according to the latest CONSORT statement (27). Families of patients with recent-onset psychosis in three outpatient clinics (N = 800 per clinic) were assessed and 290–315 of them were found eligible in this study. Two hundred ten of them (70 per clinic) were randomly selected and after baseline measurement, were then randomly allocated into one of the three study groups [Family-led Mutual Support Group (FMSG), Family Psychoeducation Group, or Treatment-As-Usual (TAU) only; 70 subjects per group]. After completion of the interventions, majority of them in the FMSG, Family Psychoeducation Group and TAU (n = 69 in each group) continued to be followed up for 48 months and only a few lost/withdrew from the study. On intention-to-treat basis, 69 in the FMSG and 68 in the other two study groups were included into final outcome analysis.
Outline of main content of family-led mutual support group program.
| Engagement (Introduction and orientation) | • Establishing mutual trust and respect | • Orientation to family group intervention and establishing trust and acceptance among members | 2 sessions |
| Awareness and addressing mutually shared psychosocial needs | • Openly sharing, understanding and showing respect and support on individual concerns and demands for caregiving | • Power resolution for control or dominance, mistrust, decision-making among group members | 4 sessions (patient included in one session) |
| Managing common and individual physical and psychosocial needs of self and family members | • Understanding and addressing about most important needs for themselves, patient and the whole family | • Discussion about each member's physical and psychosocial health needs | 4 sessions (patient included in 2 sessions) |
| Taking up caregiving roles and demands and facing with challenges | • Learning from peer members and group leader about coping and problem solving skills in caregiving and managing life situations | • Sharing of coping skills and mutual support for skill rehearsals/practices | 4 sessions |
| Group termination or continuation and future plan | • Preparation for group termination or continuation | • Preparation for and discussion on termination issues e.g. separation anxiety, independence, and continuous use of coping and stress management skills learned | 2 sessions |
The family-led mutual support group (FMSG) was modified from our previous family intervention program for people with schizophrenia (.
The FMSG program was held bi-weekly with 16 sessions for 9 months.
Socio-demographic characteristics of family participants at baseline (N = 210).
| Gender | |||||
| Male | 26 (37.1) | 24 (34.3) | 23 (32.9) | 1.80 | 0.20 |
| Female | 44 (62.9) | 46 (65.7) | 47 (67.1) | ||
| Age | M = 41.1, | M = 42.1, | M = 39.6, | 2.13 | 0.16 |
| 20–29 | 20 (28.6) | 19 (27.1) | 21 (30.0) | ||
| 30–39 | 29 (41.4) | 30 (42.9) | 30 (42.9) | ||
| 40–49 | 14 (20.0) | 15 (21.4) | 14 (20.0) | ||
| 50 or above | 7 (10.0) | 6 (8.6) | 5 (7.1) | ||
| Education level | |||||
| Primary school or below | 10 (14.3) | 11 (15.7) | 12 (17.1) | 1.34 | 0.25 |
| Secondary school | 45 (64.3) | 43 (61.4) | 45 (64.3) | ||
| University or above | 15 (21.4) | 16 (22.9) | 13 (18.6) | ||
| Relationship with patient | |||||
| Child | 16 (22.9) | 18 (25.7) | 16 (22.9) | 1.88 | 0.19 |
| Parent | 25 (35.7) | 23 (32.9) | 22 (31.4) | ||
| Spouse | 22 (31.4) | 20 (28.6) | 23 (32.9) | ||
| Others (e.g., sibling and grandparent) | 7 (10.0) | 9 (12.8) | 9 (12.8) | ||
| Monthly household income (HK$) | M = 18,730, | M = 17,500, | M = 18,330, | 1.78 | 0.17 |
| 5,000–10,000 | 10 (14.2) | 9 (12.9) | 10 (14.2) | ||
| 10,001–15,000 | 24 (34.3) | 23 (32.8) | 20 (28.6) | ||
| 15,001–25,000 | 27 (38.6) | 29 (41.4) | 31 (44.3) | ||
| 25,001–35,000 | 9 (12.9) | 9 (12.9) | 9 (12.9) | ||
| Gender | |||||
| Male | 38 (54.3) | 37 (52.9) | 36 (51.4) | 1.40 | 0.23 |
| Female | 32 (45.7) | 33 (47.1) | 34 (48.6) | ||
| Age | M = 26.8, | M = 26.2, | M = 28.9, | 1.56 | 0.22 |
| 21–29 | 40 (57.1) | 42 (60.0) | 38 (54.3) | ||
| 30–39 | 21 (30.0) | 19 (27.1) | 25 (35.7) | ||
| 40–49 | 9 (12.9) | 9 (12.9) | 7 (10.0) | ||
| Duration of illness (months) | M = 20.5, | M = 21.8, | M = 23.0, | 1.78 | 0.19 |
| 6-12 | 20 (28.6) | 19 (27.1) | 18 (25.7) | ||
| 13-24 | 23 (32.9) | 22 (31.4) | 23 (32.9) | ||
| 25-36 | 14 (20.0) | 16 (22.9) | 15 (21.4) | ||
| 37-48 | 8 (11.4) | 7 (10.0) | 9 (12.9) | ||
| 48-60 | 5 (7.1) | 6 (8.6) | 5 (7.1) | ||
| Mental condition | 2.50 | 0.11 | |||
| Worsened | 15 (21.4) | 13 (18.6) | 17 (24.3) | ||
| Stable | 40 (57.1) | 39 (55.7) | 38 (54.3) | ||
| Improved | 15 (21.4) | 18 (25.7) | 15 (21.4) | ||
| Types of oral anti-psychotics | 1.67 | 0.20 | |||
| First generation | 20 (28.5) | 18 (25.7) | 17 (24.3) | ||
| Second generation | 30 (42.9) | 31 (44.3) | 31 (42.9) | ||
| Others (e.g., Reserpine) | 10 (14.3) | 9 (12.9) | 9 (12.9) | ||
| Combined modes | 10 (14.3) | 12 (17.1) | 13 (18.6) | ||
| Dosage of medication | M = 7.34, | M = 8.38, | M = 9.76, | 1.12 | 0.33 |
| High | 10 (14.3) | 9 (12.9) | 11 (15.7) | ||
| Medium | 47 (67.1) | 48 (68.5) | 45 (64.3) | ||
| Low | 13 (18.6) | 13 (18.6) | 14 (20.0) | ||
FMSG, Family-led Mutual Support Group Program; TAU, Treatment-As-Usual only group
Frequency and percentage, f (%) or Mean and standard deviation, M and SD.
ANOVA, F.
US$1 = HK$7.8
Family caregiver's rating of patient's mental condition in the previous month, compared with that in the past year.
Dosage levels of anti-psychotic medications for psychotic patients in haloperidol equivalent mean values (65).
Mean outcome scores at all five measurements and their individual interactive (group x time) treatment effects (N = 205).
| FAD (0-50) | 8.13, 0.003 | 0.41 | ||||||
| Time 1 | 23.82 | 6.13 | 22.93 | 7.32 | 24.88 | 8.72 | ||
| Time 2 | 26.13 | 7.01 | 26.01 | 8.81 | 21.21 | 8.91 | ||
| Time 3 | 29.03 | 9.93 | 25.12 | 9.22 | 22.52 | 9.12 | ||
| Time 4 | 28.02 | 8.19 | 24.08 | 10.77 | 21.97 | 9.98 | ||
| Time 5 | 30.12 | 11.20 | 26.02 | 12.89 | 23.12 | 10.23 | ||
| FBIS (0-50) | 7.21, 0.004 | 0.35 | ||||||
| Time 1 | 30.01 | 7.12 | 30.98 | 6.45 | 31.65 | 7.77 | ||
| Time 2 | 27.13 | 8.01 | 28.12 | 8.92 | 30.08 | 8.91 | ||
| Time 3 | 25.05 | 9.13 | 26.05 | 8.73 | 30.12 | 9.65 | ||
| Time 4 | 22.12 | 10.01 | 25.63 | 9.98 | 29.22 | 9.13 | ||
| Time 5 | 19.11 | 10.98 | 27.01 | 8.92 | 30.98 | 11.21 | ||
| SLOF (43-215) | 6.51, 0.005 | 0.29 | ||||||
| Time 1 | 139.33 | 19.32 | 140.11 | 12.89 | 139.98 20.01 | |||
| Time 2 | 156.12 | 22.10 | 145.93 | 18.92 | 135.01 22.45 | |||
| Time 3 | 168.92 | 25.01 | 148.91 | 20.12 | 132.45 20.01 | |||
| Time 4 | 178.12 | 29.13 | 154.89 | 23.12 | 136.92 27.81 | |||
| Time 5 | 192.10 | 28.02 | 164.12 | 20.33 | 140.33 22.67 | |||
| Total score | 5.02, 0.005 | 0.28 | ||||||
| Time 1 | 97.12 | 10.01 | 97.67 | 9.98 | 97.12 | 10.38 | ||
| Time 2 | 82.34 | 14.23 | 86.29 | 10.33 | 98.86 | 14.59 | ||
| Time 3 | 74.11 | 15.67 | 76.56 | 11.45 | 92.12 | 16.12 | ||
| Time 4 | 60.23 | 14.12 | 77.11 | 12.78 | 101.10 | 20.66 | ||
| Time 5 | 60.87 | 16.34 | 75.55 | 14.38 | 97.65 | 19.87 | ||
| Positive symptoms | 5.13, 0.005 | 0.30 | ||||||
| Time 1 | 28.11 | 8.64 | 28.68 | 9.12 | 28.00 | 9.87 | ||
| Time 2 | 23.01 | 8.92 | 23.65 | 8.13 | 30.22 | 10.01 | ||
| Time 3 | 19.13 | 8.32 | 19.81 | 7.23 | 26.89 | 11.10 | ||
| Time 4 | 16.18 | 7.65 | 20.33 | 9.77 | 33.91 | 13.22 | ||
| Time 5 | 15.86 | 8.91 | 18.58 | 8.38 | 29.50 | 10.57 | ||
| Negative symptoms | 2.42, 0.09 | 0.08 | ||||||
| Time 1 | 21.98 | 9.01 | 22.02 | 8.56 | 21.01 | 8.12 | ||
| Time 2 | 19.79 | 8.20 | 20.13 | 9.95 | 23.91 | 9.92 | ||
| Time 3 | 17.92 | 9.33 | 18.34 | 8.73 | 20.33 | 8.72 | ||
| Time 4 | 18.01 | 7.02 | 20.01 | 9.77 | 24.01 | 7.71 | ||
| Time 5 | 17.82 | 8.34 | 17.11 | 8.22 | 20.82 | 9.69 | ||
| FSSI (1-16) | 2.34, 0.12 | 0.05 | ||||||
| Time 1 | 4.32 | 1.15 | 4.58 1.02 | 5.01 | 1.33 | |||
| Time 2 | 4.91 | 1.33 | 4.95 1.42 | 5.12 | 1.02 | |||
| Time 3 | 4.60 | 1.44 | 5.01 1.88 | 4.52 | 1.78 | |||
| Time 4 | 3.87 | 1.81 | 4.39 1.75 | 4.21 | 1.88 | |||
| Time 5 | 4.00 | 1.22 | 4.42 1.98 | 4.40 | 1.73 | |||
| Frequency/number | 6.51, 0.005 | 0.31 | ||||||
| Time 1 | 2.52 | 1.01 | 2.62 | 1.01 | 2.81 | 1.12 | ||
| Time 2 | 2.01 | 0.98 | 2.59 | 1.00 | 2.91 | 1.33 | ||
| Time 3 | 1.81 | 0.88 | 2.33 | 1.22 | 3.22 | 1.24 | ||
| Time 4 | 1.75 | 0.91 | 2.67 | 1.02 | 3.30 | 1.49 | ||
| Time 5 | 1.33 | 1.03 | 2.88 | 1.17 | 3.00 | 1.50 | ||
| Time 1 | 19.88 | 7.98 | 20.11 | 6.11 | 19.22 | 7.33 | 2.68. 0.10 | 0.08 |
| Time 2 | 16.33 | 9.13 | 17.22 | 8.45 | 22.11 | 9.34 | ||
| Time 3 | 19.12 | 10.22 | 20.34 | 6.23 | 19.12 | 10.11 | ||
| Time 4 | 17.12 | 10.01 | 20.12 | 9.33 | 19.91 | 9.88 | ||
| Time 5 | 21.23 | 11.56 | 22.11 | 13.75 | 24.11 | 11.32 | ||
FMSG, Family-led Mutual Support Group Program; TAU, Treatment-As-Usual only.
FAD, Family Assessment Device; FBIS, Family Burden Interview Schedule; FSSI, Family Support Service Index; SLOF, Specific Level of Functioning; PANSS, Positive and Negative Symptoms Scale.
Time 1, baseline measurement; Time 2, 1 week post-intervention; Time 3, 12 months post-intervention; Time 4, 24 months post-intervention; Time 5, 48 months post-intervention.
Possible range of scores of each of the outcome instruments in parenthesis.
Average duration or length of re-admissions into a psychiatric in-patient hospital/unit, in terms of average days of hospital-stay per month in the past 4-6 months at five measurements (i.e., baseline and 4 post-tests).
Helmert's contrasts test results of study outcomes with significant between-group differences.
| FMSG vs. TAU | 3.92, 1.81 | 2.83, 0.08 | 3.25-4.61 | 6.51, 0.83 | 5.83-8.21 | 6.05, 1.90 | 5.23-6.78 | 7.00, 1.02 | 6.23-7.71 | |||
| FMSG vs. Psychoeducation | 0.12, 0.48 | 0.55, 0.30 | −0.28-0.79 | 3.91, 0.82 | 2.80, 0.09 | 3.10-4.78 | 3.94, 1.98 | 2.98-5.02 | 4.10, 1.50 | 2.78-5.42 | ||
| Psychoeducation vs. TAU | 4.80, 0.35 | 4.18-5.53 | 2.60, 0.25 | 1.34, 0.12 | 2.15-2.91 | 2.11, 0.85 | 1.23, 0.16 | 1.65-3.78 | 2.90, 1.31 | 1.56, 0.10 | 1.58-4.21 | |
| FMSG vs. TAU | 2.95, 0.88 | 3.10, 0.05 | 1.98-3.81 | 5.07, 0.78 | 5.33, 0.007 | 4.21-5.86 | 7.10, 1.01 | 5.91-8.21 | 11.87, 0.45 | 10.56-2.23 | ||
| FMSG vs. Psychoeducation | 0.99, 0.80 | 0.89, 0.20 | 0.20-1.69 | 1.00, 0.50 | 0.90, 0.21 | 0.48-1.52 | 3.51, 0.35 | 3.18-3.93 | 7.90, 1.02 | 6.90-8.94 | ||
| Psychoeducation vs. TAU | 1.96, 0.05 | 1.68, 0.10 | 1.76-2.28 | 4.07, 0.88 | 4.13, 0.01 | 3.18-4.92 | 3.59, 0.82 | 2.78-4.33 | 3.97, 3.02 | 1.01-6.83 | ||
| FMSG vs. TAU | 21.11, 0.51 | 20.23-21.98 | 36.47, 4.98 | 31.45-41.26 | 41.20, 2.13 | 38.91-43.40 | 51.77, 6.13 | 48.45-57.93 | ||||
| FMSG vs. Psychoeducation | 10.19, 4.12 | 6.10-15.23 | 20.01, 4.88 | 15.89-24.91 | 23.23, 6.01 | 16.87-29.30 | 27.98, 7.95 | 9.81, 0.003 | 20.13-25.13 | |||
| Psychoeducation vs. TAU | 10.92, 4.01 | 6.82-15.13 | 16.46, 0.10 | 16.33-16.58 | 17.97, 4.56 | 13.42-22.28 | 23.79, 2.50 | 21.02-26.30 | ||||
| FMSG vs. TAU | 16.52, 0.41 | 16.00-17.01 | 18.01, 1.01 | 16.91-19.34 | 40.87, 6.34 | 33.68-47.12 | 36.78, 3.12 | 32.45-39.91 | ||||
| FMSG vs. Psychoeducation | 3.95, 3.01 | 1.89, 0.10 | 0.91-5.98 | 2.45, 3.01 | 1.12, 0.13 | −0.91-5.32 | 16.88, 1.98 | 14.46-18.51 | 14.68, 1.96 | 12.71-16.60 | ||
| Psychoeducation vs. TAU | 12.57, 4.12 | 8.40-16.71 | 15.52, 4.89 | 11.54-20.11 | 23.99, 7.12 | 16.48-31.08 | 22.11, 5.45 | 16.86-27.56 | ||||
| FMSG vs. TAU | 0.90, 0.42 | 0.48-1.34 | 1.41, 0.42 | 1.01-1.86 | 1.55, 0.50 | 1.04-2.06 | 1.67, 0.45 | 1.20-2.08 | ||||
| FMSG vs. Psychoeducation | 0.58, 0.03 | 1.12, 0.15 | 0.54-0.64 | 0.52, 0.40 | 1.20, 1.10 | 0.16-0.94 | 0.92, 0.09 | 0.86-1.04 | 1.55, 0.15 | 1.30-1.70 | ||
| Psychoeducation vs. TAU | 0.32, 0.30 | 0.98, 0.20 | 0.03-0.54 | 0.89, 0.02 | 4.03, 0.06 | 0.85-0.94 | 0.73, 0.30 | 3.75, 0.08 | 0.32-1.08 | 0.12, 0.32 | 0.82, 0.28 | −0.24-0.46 |
FMSG, Family-led Mutual Support Group Program; TAU, Treatment-As-Usual only.
FAD, Family Assessment Device; FBIS, Family Burden Interview Schedule; SLOF, Specific Level of Functioning; PANSS, Positive and Negative Symptoms Scale.
Time 2, 1 week post-intervention; Time 3, 12 months post-intervention; Time 4, 24 months post-intervention; Time 5, 48 months post-intervention.
MD, Mean score difference of an outcome measure between groups; SE, Standard error of mean difference; 95%CI, 95% Confidence Interval of mean difference.
T-test (2-tailed) was to compare the mean differences between two groups at each of the four post-tests and significant results are in an italic mode.
Average number of re-admissions into a psychiatric in-patient hospital/unit in the past 4-6 months at five measurements.
Mean and median outcome scores for completers and in-completers of the FMSG and their comparisons using Kruskal-Wallis test (N = 69).
| FAD (0-50) | 6.13, 0.11 | |||||||||
| Time 1 | 23.03 | 5.02 | 22.62 (16.85–25.71) | 23.93 | 6.39 | 24.53 (19.82–28.04) | 23.88 | 5.85 | 24.94 (20.85–27.93) | |
| Time 2 | 25.71 | 7.20 | 24.23 (17.12–28.95) | 26.01 | 8.33 | 23.92 (17.93–28.27) | 26.98 | 8.70 | 27.66 (21.92–31.63) | |
| Time 3 | 27.56 | 8.02 | 25.43 (23.43–30.12) | 28.78 | 9.45 | 27.23 (23.84–31.13) | 29.32 | 9.71 | 28.53 (22.16–32.84) | |
| Time 4 | 27.41 | 10.21 | 26.84 (22.11–32.13) | 27.23 | 10.01 | 28.84 (21.82–31.93) | 28.89 | 9.05 | 28.05 (23.85–34.53) | |
| Time 5 | 27.87 | 11.20 | 26.65 (20.21–31.67) | 29.45 | 10.78 | 28.64 (23.57–34.63) | 30.48 | 10.51 | 29.94 (21.85–37.46) | |
| FBIS (0–50) | 7.11, 0.09 | |||||||||
| Time 1 | 29.80 | 6.78 | 30.64 (23.82–34.94) | 29.91 | 6.81 | 28.26 (20.14–31.93) | 30.33 | 6.02 | 29.62 (20.01–29.84) | |
| Time 2 | 27.96 | 8.43 | 28.95 (20.81–33.55) | 27.46 | 8.03 | 26.85 (20.80–32.54) | 27.03 | 8.76 | 27.03 (17.27–26.82) | |
| Time 3 | 25.98 | 9.71 | 26.65 (19.25–30.84) | 25.11 | 8.98 | 24.64 (20.10–29.35) | 24.81 | 8.60 | 23.54 (19.81–27.03) | |
| Time 4 | 24.34 | 10.21 | 25.44 (18.88–31.12) | 23.68 | 9.12 | 25.06 (19.60–30.73) | 21.90 | 9.98 | 22.26 (16.64–24.92) | |
| Time 5 | 21.33 | 10.45 | 22.65 (16.15–27.98) | 19.58 | 9.98 | 20.23 (17.30–27.26) | 19.02 | 11.20 | 20.17 (15.13–24.86) | |
| SLOF (43–215) | 4.89, 0.13 | |||||||||
| Time 1 | 140.31 | 14.54 | 138.61 (116.85–145.72) | 138.12 | 15.34 | 139.64 (126.53–149.82) | 140.35 | 17.29 | 139.29 (117.22–156.75) | |
| Time 2 | 154.11 | 20.01 | 151.13 (136.15–178.14) | 157.90 | 19.32 | 160.33 (120.80–179.32) | 158.33 | 20.34 | 160.11 (129.81–185.92) | |
| Time 3 | 162.88 | 24.78 | 157.22 (120.82–171.23) | 167.33 | 22.12 | 170.12 (144.20–189.24) | 170.55 | 22.71 | 138.65 (116.81–145.72) | |
| Time 4 | 165.10 | 28.11 | 158.03 (111.24–175.91) | 179.33 | 25.33 | 175.04 (118.81–198.13) | 180.22 | 20.88 | 182.49 (135.05–199.45) | |
| Time 5 | 170.19 | 29.87 | 168.54 (114.91–179.62) | 190.10 | 23.30 | 188.01 (129.50–199.81) | 193.13 | 25.77 | 194.82 (140.89–221.81) | |
| PANSS (30–210) | ||||||||||
| Total score | 5.98, 0.12 | |||||||||
| Time 1 | 99.38 | 9.33 | 98.61 (81.85–107.53) | 98.67 | 9.02 | 97.55 (75.80–108.34) | 97.12 | 11.45 | 98.22 (77.71–108.86) | |
| Time 2 | 86.58 | 11.22 | 87.63 (81.82–107.51) | 82.77 | 12.44 | 83.91 (61.77–97.50) | 82.10 | 14.59 | 81.46 (69.65–96.12) | |
| Time 3 | 77.82 | 17.55 | 75.32 (65.11–88.92) | 75.11 | 13.56 | 77.44 (62.89–96.22) | 72.80 | 15.67 | 73.23 (61.99–79.88) | |
| Time 4 | 68.20 | 16.44 | 65.11 (59.88–79.45) | 61.12 | 10.56 | 60.15 (53.01–84.65) | 60.05 | 12.71 | 62.65 (50.33–79.25) | |
| Time 5 | 67.55 | 15.22 | 69.13 (51.90–87.23) | 62.02 | 13.65 | 64.87 (51.67–87.22) | 59.66 | 13.81 | 57.86 (50.31–68.83) | |
| Positive symptoms | 5.01, 0.14 | |||||||||
| Time 1 | 27.93 | 7.60 | 27.36 (24.31–29.98) | 29.33 | 8.23 | 29.21 (21.31–27.98) | 28.56 | 8.71 | 28.00 (23.25–31.57) | |
| Time 2 | 23.54 | 7.88 | 23.39 (19.26–28.75) | 23.55 | 9.13 | 24.55 (19.48–28.67) | 22.99 | 9.31 | 23.48 (19.45–26.79) | |
| Time 3 | 21.43 | 10.32 | 24.12 (19.22–30.44) | 20.21 | 7.88 | 21.87 (18.12–26.54) | 19.00 | 9.13 | 18.92 (15.11–26.15) | |
| Time 4 | 19.27 | 10.65 | 20.89 (16.58–28.83) | 18.13 | 8.44 | 19.23 (16.33–25.12) | 16.01 | 8.72 | 17.58 (13.22–23.78) | |
| Time 5 | 18.71 | 10.90 | 19.94 (14.71–27.69) | 17.08 | 7.23 | 18.81 (16.51–24.92) | 15.19 | 7.22 | 15.96 (13.01–20.68) | |
| Negative symptoms | 4.42, 0.17 | |||||||||
| Time 1 | 21.43 | 7.88 | 22.31 (19.44–27.12) | 22.00 | 7.12 | 23.00 (20.12–26.43) | 22.11 | 8.00 | 21.55 (18.76–25.41) | |
| Time 2 | 20.45 | 9.56 | 21.45 (16.45–28.76) | 19.32 | 9.38 | 20.13 (18.24–25.89) | 19.98 | 9.35 | 19.01 (15.31–26.78) | |
| Time 3 | 19.90 | 9.77 | 20.98 (16.21–28.13) | 17.01 | 9.71 | 18.13 (16.30–25.13) | 17.30 | 8.52 | 16.78 (12.88–20.66) | |
| Time 4 | 19.45 | 10.22 | 21.56 (16.00–29.02) | 17.33 | 9.88 | 17.12 (14.20–24.02) | 17.95 | 8.79 | 18.32 (13.22–25.02) | |
| Time 5 | 19.80 | 9.64 | 20.96 (17.21–28.31) | 17.69 | 8.98 | 19.01 (15.03–25.47) | 17.86 | 9.69 | 18.61 (13.54–24.25) | |
| FSSI (1–16) | 3.02, 0.25 | |||||||||
| Time 1 | 4.23 | 1.01 | 4.08 (3.23–5.45) | 4.30 | 1.08 | 4.41 (3.01–5.11) | 4.58 | 1.02 | 4.48 (3.12–5.61) | |
| Time 2 | 4.90 | 1.10 | 4.50 (2.87–6.85) | 4.96 | 1.12 | 4.65 (2.97–5.98) | 4.85 | 0.98 | 4.79 (2.01–6.99) | |
| Time 3 | 4.23 | 1.27 | 4.51 (2.23–7.67) | 4.76 | 1.18 | 4.99 (2.86–6.90) | 4.60 | 1.12 | 4.59 (2.35–7.02) | |
| Time 4 | 3.80 | 1.22 | 4.22 (3.01–7.58) | 3.98 | 1.31 | 3.88 (2.14–7.05) | 3.88 | 1.33 | 3.78 (2.61–5.98) | |
| Time 5 | 4.10 | 1.33 | 4.30 (2.56–6.73) | 3.89 | 1.11 | 4.15 (2.90–6.98) | 4.00 | 1.15 | 4.10 (2.31–6.65) | |
| Frequency/number | 5.27, 0.15 | |||||||||
| Time 1 | 2.60 | 1.11 | 2.58 (1.00–5.00) | 2.68 | 1.04 | 2.89 (1.00–5.00) | 2.65 | 1.01 | 2.80 (0.00–5.00) | |
| Time 2 | 2.10 | 0.99 | 2.01 (0.00–4.00) | 2.08 | 1.22 | 2.21 (1.00–4.00) | 2.01 | 1.22 | 2.00 (0.00–6.00) | |
| Time 3 | 1.99 | 1.42 | 2.25 (1.00–4.00) | 1.81 | 1.32 | 1.98 (1.00–4.00) | 1.80 | 1.33 | 2.00 (0.00–6.00) | |
| Time 4 | 1.90 | 1.33 | 2.35 (1.00–4.00) | 1.89 | 1.21 | 1.78 (0.00–5.00) | 1.72 | 1.19 | 1.82 (0.00–4.00) | |
| Time 5 | 1.93 | 1.35 | 2.15 (1.00–4.00) | 1.88 | 1.33 | 2.98 (1.00–6.00) | 1.30 | 1.11 | 1.40 (0.00–3.00) | |
FMSG, Family-led Mutual Support Group Program.
FAD, Family Assessment Device; FBIS, Family Burden Interview Schedule; FSSI, Family Support Service Index; SLOF, Specific Level of Functioning; PANSS, Positive and Negative Symptoms Scale.
Time 1, baseline measurement; Time 2, one week post-intervention; Time 3, 12 months post-intervention; Time 4, 24 months post-intervention; Time 5, 48 months post-intervention.
Possible range of scores of each of the outcome instruments in parenthesis.